BMS-833923

CAS No. 1059734-66-5

BMS-833923( XL-139 )

Catalog No. M17789 CAS No. 1059734-66-5

BMS-833923, an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 41 In Stock
10MG 67 In Stock
25MG 116 In Stock
50MG 187 In Stock
100MG 338 In Stock
200MG 498 In Stock
500MG 790 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BMS-833923
  • Note
    Research use only, not for human use.
  • Brief Description
    BMS-833923, an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).
  • Description
    BMS-833923, an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    XL-139
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    Smoothened
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1059734-66-5
  • Formula Weight
    473.57
  • Molecular Formula
    C30H27N5O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 50 mg/mL 105.58 mM;
  • SMILES
    c12c(c(nc(n1)Nc1ccc(cc1)C(=O)Nc1cc(ccc1C)CNC)c1ccccc1)cccc2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tang JY, et al. Semin Cutan Med Surg. 2011, 30(4 Suppl), S14-18.2. Zaidi AH, et al. Y Invest. 2013, 31(7), 480-489.
molnova catalog
related products
  • Secukinumab B

    Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

  • Diallyl disulfide

    Diallyl disulfide has antitumor effect, the effect can be enhanced by miR-200b and miR-22.

  • Ayanin

    Ayanin has vasorelaxant activity, it also may have the potential for use in treating allergic asthma. The IC50 value of Ayanin is 2.2microM for inhibiting interleukin IL-4 production from purified basophils. Ayanin is a non-selective phosphodiesterase1-4 inhibitor and can be used for respiratory disease researches.